These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16333527)

  • 41. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
    Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
    Pohorelic B; Singh R; Parkin S; Koro K; Yang AD; Egan C; Magliocco A
    Breast Cancer Res Treat; 2012 May; 133(1):201-14. PubMed ID: 21894461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of Src activation with cardiotoxin III blocks migration and invasion of MDA-MB-231 cells.
    Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR
    Toxicon; 2013 Nov; 74():56-67. PubMed ID: 23933586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
    Chen LC; Tu SH; Huang CS; Chen CS; Ho CT; Lin HW; Lee CH; Chang HW; Chang CH; Wu CH; Lee WS; Ho YS
    Breast Cancer Res Treat; 2012 Aug; 134(3):989-1004. PubMed ID: 22434522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor.
    Larroque-Lombard AL; Ning N; Rao S; Lauwagie S; Halaoui R; Coudray L; Huang Y; Jean-Claude BJ
    Chem Biol Drug Des; 2012 Dec; 80(6):981-91. PubMed ID: 22943437
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
    Larsen SL; Laenkholm AV; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    PLoS One; 2015; 10(2):e0118346. PubMed ID: 25706943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
    Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
    Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
    Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
    Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
    Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
    Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
    Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
    Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway.
    Sukocheva O; Wang L; Verrier E; Vadas MA; Xia P
    Endocrinology; 2009 Oct; 150(10):4484-92. PubMed ID: 19706837
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ZIP7-mediated intracellular zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
    Taylor KM; Vichova P; Jordan N; Hiscox S; Hendley R; Nicholson RI
    Endocrinology; 2008 Oct; 149(10):4912-20. PubMed ID: 18583420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
    Elsberger B
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):343-51. PubMed ID: 24388104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
    Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
    Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
    Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.
    Campbell PS; Mavingire N; Khan S; Rowland LK; Wooten JV; Opoku-Agyeman A; Guevara A; Soto U; Cavalli F; Loaiza-Pérez AI; Nagaraj G; Denham LJ; Adeoye O; Jenkins BD; Davis MB; Schiff R; Brantley EJ
    J Cell Physiol; 2018 Jan; 234(1):108-121. PubMed ID: 30076704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.